{"id":526128,"date":"2021-08-10T14:33:06","date_gmt":"2021-08-10T18:33:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/"},"modified":"2021-08-10T14:33:06","modified_gmt":"2021-08-10T18:33:06","slug":"mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/","title":{"rendered":"MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases"},"content":{"rendered":"

<\/p>\n

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases<\/b><\/p>\n

Patent protects Supera-CBD, shown to be 7-8X more effective than plant-derived CBD in reducing enzymes that play a key role in pain, inflammation, and neurodegeneration<\/i><\/p>\n

BALTIMORE–(BUSINESS WIRE<\/a>)–MyMD Pharmaceuticals, Inc.<\/a> (Nasdaq: MYMD) (\u201cMyMD\u201d or \u201cthe Company\u201d), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled \u201cSynthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.\u201d\n<\/p>\n

\nThe patent protects the Company\u2019s drug candidate Supera-CBD<\/a>, a synthetic cannabidiol derivative that targets cannabinoid receptor type 2 (CB2) for the treatment of neuroinflammatory and neurodegenerative diseases. It also protects pharmaceutical compositions containing the Supera-CBD compound. Supera-CBD is being developed to address anxiety, chronic pain, addiction, and seizures, and is on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.\n<\/p>\n

\n\u201cSupera-CBD has the potential to address the significant unmet need for medications to treat stimulant addictions, specifically cocaine, methamphetamine and opioids, which currently have no approved treatment,\u201d said Chris Chapman, M.D., President, Director and Chief Medical Officer of MyMD. \u201cThis first patent for Supera-CBD will support our discovery efforts as we move forward with this platform as a major focus for our Company. It also diversifies and strengthens our growing intellectual property position, which already contains 11 granted patents for our MYMD-1 drug platform.\u201d\n<\/p>\n

\nSupera-CBD is a non-toxic, synthetic, preclinical cannabidiol derivative that has been shown in in vitro studies to be approximately 7-8x more effective than plant-derived CBD in inhibiting MAO-A and MAO-B enzymes, and more than 3x more effective than plant-derived CBD in inhibiting CB2. These superior efficacies enhance Supera-CBD\u2019s therapeutic potential to treat pain, inflammation, and neurodegeneration, as well as substance addiction.\n<\/p>\n

\n\u201cSupera-CBD shows great promise that it can provide all the benefits of plant-based CBD, at a stronger and more efficient level,\u201d said Adam Kaplin, M.D., Ph.D., Chief Scientific Officer for MyMD. \u201cWe are eager to see this drug move forward to help the many who have long-awaited the relief that we believe it can provide. By addressing an unmet need for pharmaceutical cannabinoids, Supera-CBD is positioned to become a prescription drug alternative to unregulated CBD.\u201d\n<\/p>\n

About MyMD Pharmaceuticals, Inc.<\/b><\/p>\n

\nMyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) is a clinical stage pharmaceutical company committed to extending healthy lifespan in humans by focusing on developing two therapeutic platforms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-\u03b1 and other pro-inflammatory cytokines. MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-\u03b1 blocking drugs, and aging and longevity. The Company\u2019s second drug platform, Supera-CBD, is based on a novel synthetic derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase. Supera-CBD is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug. For more information, visit www.mymd.com<\/a>.\n<\/p>\n

Cautionary Statement Regarding Forward-Looking Statements<\/b><\/p>\n

\nThis press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would” and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the timing of, and MyMD\u2019s ability to, obtain and maintain regulatory approvals for clinical trials of MyMD\u2019s pharmaceutical candidates; the timing and results of MyMD\u2019s planned clinical trials for its pharmaceutical candidates; the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD\u2019s ability to retain and attract senior management and other key employees; MyMD\u2019s ability to quickly and effectively respond to new technological developments; MyMD\u2019s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMD\u2019s proprietary rights; and the impact of the ongoing COVID-19 pandemic on MyMD\u2019s results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth in the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021, filed by MyMD on May 18, 2021. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210810005909\/en\/<\/a><\/span><\/p>\n

Investor Contact:
\n<\/b>
Robert Schatz
\n
(646) 421-9523
\n
rschatz@mymd.com
\n<\/a>
www.mymd.com<\/a><\/p>\n

Media Contact:
\n<\/b>
Will Johnson
\n
201-465-8019
\n
MYMD@antennagroup.com
\n<\/a>
www.antennagroup.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Maryland<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases Patent protects Supera-CBD, shown to be 7-8X more effective than plant-derived CBD in reducing enzymes that play a key role in pain, inflammation, and neurodegeneration BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (\u201cMyMD\u201d or \u201cthe Company\u201d), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled \u201cSynthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.\u201d The patent protects the Company\u2019s drug candidate Supera-CBD, a synthetic cannabidiol derivative that targets cannabinoid receptor type 2 (CB2) for the … <\/p>\n

Continue reading “MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-526128","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases Patent protects Supera-CBD, shown to be 7-8X more effective than plant-derived CBD in reducing enzymes that play a key role in pain, inflammation, and neurodegeneration BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (\u201cMyMD\u201d or \u201cthe Company\u201d), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled \u201cSynthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.\u201d The patent protects the Company\u2019s drug candidate Supera-CBD, a synthetic cannabidiol derivative that targets cannabinoid receptor type 2 (CB2) for the … Continue reading "MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-10T18:33:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210810005909r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases\",\"datePublished\":\"2021-08-10T18:33:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\\\/\"},\"wordCount\":917,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210810005909r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\\\/\",\"name\":\"MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210810005909r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-08-10T18:33:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210810005909r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210810005909r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/","og_locale":"en_US","og_type":"article","og_title":"MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases - Market Newsdesk","og_description":"MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases Patent protects Supera-CBD, shown to be 7-8X more effective than plant-derived CBD in reducing enzymes that play a key role in pain, inflammation, and neurodegeneration BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (\u201cMyMD\u201d or \u201cthe Company\u201d), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled \u201cSynthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.\u201d The patent protects the Company\u2019s drug candidate Supera-CBD, a synthetic cannabidiol derivative that targets cannabinoid receptor type 2 (CB2) for the … Continue reading \"MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-10T18:33:06+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210810005909r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases","datePublished":"2021-08-10T18:33:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/"},"wordCount":917,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210810005909r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/","name":"MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210810005909r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-08-10T18:33:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210810005909r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210810005909r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-announces-issuance-of-u-s-patent-for-synthetic-cannabinoid-compounds-for-treating-neuroinflammatory-and-neurodegenerative-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/526128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=526128"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/526128\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=526128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=526128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=526128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}